WAYNE GOODMAN to Middle Aged
This is a "connection" page, showing publications WAYNE GOODMAN has written about Middle Aged.
Connection Strength
0.961
-
Randomized Controlled Trial of the Effects of High-Dose Ondansetron on Clinical Symptoms and Brain Connectivity in Obsessive-Compulsive and Tic Disorders. Am J Psychiatry. 2025 Mar 01; 182(3):285-296.
Score: 0.059
-
Deep Brain Stimulation for Obsessive-Compulsive Disorder: Optimal Stimulation Sites. Biol Psychiatry. 2024 Jul 15; 96(2):101-113.
Score: 0.055
-
Impact of the COVID-19 pandemic on exposure and response prevention outcomes in adults and youth with obsessive-compulsive disorder. Psychiatry Res. 2021 01; 295:113597.
Score: 0.044
-
Psychiatric Diagnoses and Medications for Hurricane Harvey Sheltered Evacuees. Community Ment Health J. 2019 10; 55(7):1099-1102.
Score: 0.040
-
Altered olfactory processing and increased insula activity in patients with obsessive-compulsive disorder: An fMRI study. Psychiatry Res Neuroimaging. 2017 Apr 30; 262:15-24.
Score: 0.034
-
Neural correlates of emotional response inhibition in obsessive-compulsive disorder: A preliminary study. Psychiatry Res. 2015 Nov 30; 234(2):259-64.
Score: 0.031
-
The Persistence of Experience: Prior Attentional and Emotional State Affects Network Functioning in a Target Detection Task. Cereb Cortex. 2015 Sep; 25(9):3235-48.
Score: 0.028
-
The role of avoidance in the phenomenology of obsessive-compulsive disorder. Compr Psychiatry. 2012 Feb; 53(2):187-94.
Score: 0.023
-
Psychometric analysis of the Yale-Brown Obsessive-Compulsive Scale Second Edition Symptom Checklist. J Anxiety Disord. 2010 Aug; 24(6):650-6.
Score: 0.021
-
Concurrent validity of the Yale-Brown Obsessive-Compulsive Scale-Symptom Checklist. J Clin Psychol. 2008 Dec; 64(12):1338-51.
Score: 0.019
-
Cognitive-behavioral therapy for obsessive-compulsive disorder: a non-randomized comparison of intensive and weekly approaches. J Anxiety Disord. 2008 Oct; 22(7):1146-58.
Score: 0.018
-
Florida Obsessive-Compulsive Inventory: development, reliability, and validity. J Clin Psychol. 2007 Sep; 63(9):851-9.
Score: 0.018
-
D-cycloserine does not enhance exposure-response prevention therapy in obsessive-compulsive disorder. Int Clin Psychopharmacol. 2007 Jul; 22(4):230-7.
Score: 0.018
-
Effect of comorbid tics on a clinically meaningful response to 8-week open-label trial of fluoxetine in obsessive compulsive disorder. J Psychiatr Res. 2007 Apr-Jun; 41(3-4):332-7.
Score: 0.016
-
Clinical predictors of early fluoxetine treatment response in obsessive-compulsive disorder. Depress Anxiety. 2006; 23(7):429-33.
Score: 0.016
-
Hope and coping in family members of patients with obsessive-compulsive disorder. J Anxiety Disord. 2006; 20(5):614-29.
Score: 0.015
-
Treatment of generalized anxiety disorder with escitalopram: pooled results from double-blind, placebo-controlled trials. J Affect Disord. 2005 Aug; 87(2-3):161-7.
Score: 0.015
-
Psychometric properties of the Spanish Yale-Brown Obsessive-Compulsive Scale - Second Edition. Psychiatry Res. 2025 Jun; 348:116456.
Score: 0.015
-
Escitalopram for the treatment of GAD: efficacy across different subgroups and outcomes. Ann Clin Psychiatry. 2005 Apr-Jun; 17(2):71-5.
Score: 0.015
-
Yale-Brown Obsessive Compulsive Scale: the dimensional structure revisited. Depress Anxiety. 2005; 22(1):28-35.
Score: 0.015
-
Aperiodic spectral slope tracks the effects of brain state on saliency responses in the human auditory cortex. Sci Rep. 2024 12 28; 14(1):30751.
Score: 0.015
-
Aperiodic (1/f) Neural Activity Robustly Tracks Symptom Severity Changes in Treatment-Resistant Depression. Biol Psychiatry Cogn Neurosci Neuroimaging. 2025 Feb; 10(2):186-194.
Score: 0.015
-
Psychometric Properties of the Yale-Brown Obsessive Compulsive Scale-II Self-Report. J Psychiatr Pract. 2024 Nov 01; 30(6):421-427.
Score: 0.015
-
Misconceptions Among Mental Health Treatment Providers About OCD and PTSD. Behav Ther. 2025 05; 56(3):470-486.
Score: 0.014
-
Beta activity in human anterior cingulate cortex mediates reward biases. Nat Commun. 2024 Jul 15; 15(1):5528.
Score: 0.014
-
Disruption of neural periodicity predicts clinical response after deep brain stimulation for obsessive-compulsive disorder. Nat Med. 2024 Oct; 30(10):3004-3014.
Score: 0.014
-
A Low-Intensity Transcranial Focused Ultrasound Parameter Exploration Study of the Ventral Capsule/Ventral Striatum. Neuromodulation. 2025 Jan; 28(1):146-154.
Score: 0.014
-
A double-blind, placebo-controlled trial of olanzapine addition in fluoxetine-refractory obsessive-compulsive disorder. Biol Psychiatry. 2004 Mar 01; 55(5):553-5.
Score: 0.014
-
Brain activation by disgust-inducing pictures in obsessive-compulsive disorder. Biol Psychiatry. 2003 Oct 01; 54(7):751-6.
Score: 0.014
-
Tractography-Based Modeling Explains Treatment Outcomes in Patients Undergoing Deep Brain Stimulation for Obsessive-Compulsive Disorder. Biol Psychiatry. 2024 Jul 15; 96(2):95-100.
Score: 0.013
-
Intraoperative valence testing to adjudicate between ventral capsule/ventral striatum and bed nucleus of the stria terminalis target selection in deep brain stimulation for obsessive-compulsive disorder. J Neurosurg. 2023 08 01; 139(2):442-450.
Score: 0.013
-
Topiramate attenuates self-injurious behaviour in Prader-Willi Syndrome. Int J Neuropsychopharmacol. 2002 Jun; 5(2):141-5.
Score: 0.012
-
Provider perceptions of telehealth and in-person exposure and response prevention for obsessive-compulsive disorder. Psychiatry Res. 2022 07; 313:114610.
Score: 0.012
-
Cost-effectiveness analysis of deep transcranial magnetic stimulation relative to evidence-based strategies for treatment-refractory obsessive-compulsive disorder. J Psychiatr Res. 2022 02; 146:50-54.
Score: 0.012
-
A randomized proof-of-mechanism trial applying the 'fast-fail' approach to evaluating ?-opioid antagonism as a treatment for anhedonia. Nat Med. 2020 05; 26(5):760-768.
Score: 0.011
-
Serious negative consequences associated with exposure and response prevention for obsessive-compulsive disorder: A survey of therapist attitudes and experiences. Depress Anxiety. 2020 05; 37(5):418-428.
Score: 0.011
-
Development and psychometric evaluation of the Mandarin Chinese version of the Yale-Brown Obsessive-Compulsive Scale - Second Edition. Braz J Psychiatry. 2019 Nov-Dec; 41(6):494-498.
Score: 0.010
-
Changes in Dosing and Dose Timing of D-Cycloserine Explain Its Apparent Declining Efficacy for Augmenting Exposure Therapy for Anxiety-related Disorders: An Individual Participant-data Meta-analysis. J Anxiety Disord. 2019 12; 68:102149.
Score: 0.010
-
Effects of left frontal transcranial magnetic stimulation on depressed mood, cognition, and corticomotor threshold. Biol Psychiatry. 1999 Jun 01; 45(11):1440-6.
Score: 0.010
-
Efficacy and Safety of Deep Transcranial Magnetic Stimulation for Obsessive-Compulsive Disorder: A Prospective Multicenter Randomized Double-Blind Placebo-Controlled Trial. Am J Psychiatry. 2019 11 01; 176(11):931-938.
Score: 0.010
-
Incidence and clinical correlates of anger attacks in Chinese patients with obsessive-compulsive disorder. J Zhejiang Univ Sci B. 2019 Apr.; 20(4):363-370.
Score: 0.010
-
Pharmacological risk factors associated with hospital readmission rates in a psychiatric cohort identified using prescriptome data mining. BMC Med Inform Decis Mak. 2018 09 14; 18(Suppl 3):79.
Score: 0.010
-
Politically-focused intrusive thoughts and associated ritualistic behaviors in a community sample. J Anxiety Disord. 2018 05; 56:35-42.
Score: 0.009
-
Treatment of obsessive-compulsive disorder with fluvoxamine: a multicentre, double-blind, placebo-controlled trial. Int Clin Psychopharmacol. 1996 Mar; 11(1):21-9.
Score: 0.008
-
Ketamine for rapid reduction of suicidal ideation: a randomized controlled trial. Psychol Med. 2015 Dec; 45(16):3571-80.
Score: 0.008
-
m-Chlorophenylpiperazine in patients with obsessive-compulsive disorder: absence of symptom exacerbation. Biol Psychiatry. 1995 Aug 01; 38(3):138-49.
Score: 0.008
-
Deep Brain Stimulation for Obsessive-Compulsive Disorder: A Meta-Analysis of Treatment Outcome and Predictors of Response. PLoS One. 2015; 10(7):e0133591.
Score: 0.008
-
Double-blind, placebo-controlled, pilot trial of paliperidone augmentation in serotonin reuptake inhibitor-resistant obsessive-compulsive disorder. J Clin Psychiatry. 2013 Jun; 74(6):e527-32.
Score: 0.007
-
Long-term outcome in adults with obsessive-compulsive disorder. Depress Anxiety. 2013 Aug; 30(8):716-22.
Score: 0.007
-
The relationship between insight and control in obsessive-compulsive disorder: implications for the insanity defense. Bull Am Acad Psychiatry Law. 1993; 21(2):245-52.
Score: 0.006
-
Rebound symptoms following battery depletion in the NIH OCD DBS cohort: clinical and reimbursement issues. Brain Stimul. 2012 Oct; 5(4):599-604.
Score: 0.006
-
Cerebral laterality, perception of emotion, and treatment response in obsessive-compulsive disorder. Biol Psychiatry. 1991 May 01; 29(9):900-8.
Score: 0.006
-
Refining clinical judgment of treatment outcome in obsessive-compulsive disorder. Psychiatry Res. 2011 Feb 28; 185(3):394-401.
Score: 0.005
-
Suicidality and risk of suicide--definition, drug safety concerns, and a necessary target for drug development: a brief report. J Clin Psychiatry. 2010 Aug; 71(8):1040-6.
Score: 0.005
-
Right and left dorsolateral pre-frontal rTMS treatment of refractory depression: a randomized, sham-controlled trial. Psychiatry Res. 2010 Aug 15; 178(3):467-74.
Score: 0.005
-
Smile and laughter induction and intraoperative predictors of response to deep brain stimulation for obsessive-compulsive disorder. Neuroimage. 2011 Jan; 54 Suppl 1:S247-55.
Score: 0.005
-
Dimensional predictors of response to SRI pharmacotherapy in obsessive-compulsive disorder. J Affect Disord. 2010 Feb; 121(1-2):175-9.
Score: 0.005
-
Deep brain stimulation of the ventral internal capsule/ventral striatum for obsessive-compulsive disorder: worldwide experience. Mol Psychiatry. 2010 Jan; 15(1):64-79.
Score: 0.005
-
Associations between miscellaneous symptoms and symptom dimensions in adults with obsessive-compulsive disorder. Anxiety Stress Coping. 2008 Apr; 21(2):199-212.
Score: 0.005
-
A pilot study of vagus nerve stimulation (VNS) for treatment-resistant anxiety disorders. Brain Stimul. 2008 Apr; 1(2):112-21.
Score: 0.005
-
Three-year outcomes in deep brain stimulation for highly resistant obsessive-compulsive disorder. Neuropsychopharmacology. 2006 Nov; 31(11):2384-93.
Score: 0.004
-
Ineffectiveness of clonidine in the treatment of the benzodiazepine withdrawal syndrome: report of three cases. Am J Psychiatry. 1986 Jul; 143(7):900-3.
Score: 0.004
-
Obsessive compulsive symptoms in schizophrenia: frequency and clinical features. Schizophr Res. 2005 Jul 15; 76(2-3):309-16.
Score: 0.004
-
A double-blind, placebo-controlled study of the efficacy and safety of controlled-release fluvoxamine in patients with obsessive-compulsive disorder. J Clin Psychiatry. 2003 Jun; 64(6):640-7.
Score: 0.003
-
Cerebral blood flow changes in depressed patients after treatment with repetitive transcranial magnetic stimulation: evidence of individual variability. Neuropsychiatry Neuropsychol Behav Neurol. 2002 Sep; 15(3):159-75.
Score: 0.003
-
Symptom stability in adult obsessive-compulsive disorder: data from a naturalistic two-year follow-up study. Am J Psychiatry. 2002 Feb; 159(2):263-8.
Score: 0.003
-
Long-term treatment of obsessive-compulsive disorder after an acute response: a comparison of fluoxetine versus placebo. J Clin Psychopharmacol. 2001 Feb; 21(1):46-52.
Score: 0.003
-
Effects of the CCK(B) antagonist CI-988 on responses to mCPP in generalized anxiety disorder. Psychiatry Res. 1999 Mar 22; 85(3):225-40.
Score: 0.002
-
A preliminary study of tryptophan depletion on tics, obsessive-compulsive symptoms, and mood in Tourette's syndrome. Biol Psychiatry. 1997 Jan 01; 41(1):117-21.
Score: 0.002
-
Elevated cerebrospinal fluid corticotropin-releasing factor in Tourette's syndrome: comparison to obsessive compulsive disorder and normal controls. Biol Psychiatry. 1996 May 01; 39(9):776-83.
Score: 0.002
-
Lack of efficacy of clozapine monotherapy in refractory obsessive-compulsive disorder. Am J Psychiatry. 1995 Dec; 152(12):1812-4.
Score: 0.002
-
A case-controlled study of repetitive thoughts and behavior in adults with autistic disorder and obsessive-compulsive disorder. Am J Psychiatry. 1995 May; 152(5):772-7.
Score: 0.002
-
Family accommodation in obsessive-compulsive disorder. Am J Psychiatry. 1995 Mar; 152(3):441-3.
Score: 0.002
-
Cerebrospinal fluid biogenic amines in obsessive compulsive disorder, Tourette's syndrome, and healthy controls. Neuropsychopharmacology. 1995 Feb; 12(1):73-86.
Score: 0.002
-
A family study of obsessive-compulsive disorder. Am J Psychiatry. 1995 Jan; 152(1):76-84.
Score: 0.002
-
Effects of tryptophan depletion in panic disorder. Biol Psychiatry. 1994 Dec 01; 36(11):775-7.
Score: 0.002
-
Elevated cerebrospinal fluid levels of oxytocin in obsessive-compulsive disorder. Comparison with Tourette's syndrome and healthy controls. Arch Gen Psychiatry. 1994 Oct; 51(10):782-92.
Score: 0.002
-
A multicenter investigation of fixed-dose fluoxetine in the treatment of obsessive-compulsive disorder. Arch Gen Psychiatry. 1994 Jul; 51(7):559-67.
Score: 0.002
-
"Just right" perceptions associated with compulsive behavior in Tourette's syndrome. Am J Psychiatry. 1994 May; 151(5):675-80.
Score: 0.002
-
Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder. A double-blind, placebo-controlled study in patients with and without tics. Arch Gen Psychiatry. 1994 Apr; 51(4):302-8.
Score: 0.002
-
Tryptophan depletion in patients with obsessive-compulsive disorder who respond to serotonin reuptake inhibitors. Arch Gen Psychiatry. 1994 Apr; 51(4):309-17.
Score: 0.002
-
Physical symptoms associated with paroxetine discontinuation. Am J Psychiatry. 1994 Feb; 151(2):289.
Score: 0.002
-
Tic-related vs. non-tic-related obsessive compulsive disorder. Anxiety. 1994-1995; 1(5):208-15.
Score: 0.002
-
Effects of the serotonin reuptake inhibitor fluvoxamine on yohimbine-induced anxiety in panic disorder. Psychiatry Res. 1993 Aug; 48(2):119-33.
Score: 0.002
-
A controlled trial of lithium augmentation in fluvoxamine-refractory obsessive-compulsive disorder: lack of efficacy. J Clin Psychopharmacol. 1991 Jun; 11(3):175-84.
Score: 0.001
-
Results of a double-blind placebo controlled trial of a new serotonin uptake inhibitor, sertraline, in the treatment of obsessive-compulsive disorder. Psychopharmacol Bull. 1990; 26(3):279-84.
Score: 0.001
-
Pathophysiology of obsessive-compulsive disorder. Am J Psychiatry. 1989 Oct; 146(10):1350-1.
Score: 0.001
-
Carbon dioxide-induced anxiety. Behavioral, physiologic, and biochemical effects of carbon dioxide in patients with panic disorders and healthy subjects. Arch Gen Psychiatry. 1988 Jan; 45(1):43-52.
Score: 0.001